Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.

In this multicentric random double-blind study versus placebo, the therapeutic activity of timed-release dihydroergotamine preparation 10 mg/per os/day has been tested in 90 patients affected by common migraine. The drug presented a prophylactic effect on recurrent headache, mainly on night and awakening migraine. A low incidence of side-effects with no weight changes or other effects on physiologic events was registered.

RCT Entities:   Population Interventions Outcomes